托吡酯与卡马西平治疗癫痫部分性发作疗效及安全性Meta分析  

Meta-analysis of the efficacy and safety of TPM and carbamazepine in the treatment of partial epilepsy

作　　者：朱亚峰 曾皎 顾家鹏 郭言 张晓莉[1] 张萍[1] 张帆[1] 韩永凯[1] 王旭生[1] 杜爱玲[1] 费鹏鸽[1] 顾仁骏[1] Zhu Yafeng;Zeng Jiao;Gu Jiapeng;Guo Yan;Zhang Xiaoli;Zhang Ping;Zhang Fan;Han Yong-kai;Wang Xusheng;Du Ailing;Fei Pengge;Gu Renjun(First author's address The Second Affiliated Hospital of Xinxriang Medical College,Xinxiang 453002,Henan,China)

机构地区：[1]新乡医学院第二附属医院,河南新乡453002 [2]河南省直第三人民医院,河南郑州450000

出　　处：《临床心身疾病杂志》2020年第6期12-19,共8页Journal of Clinical Psychosomatic Diseases

基　　金：河南省卫生和计划生育委员会科技攻关计划资助项目(编号201403136);河南省教育厅高等学校重点科研资助项目(编号17A320028)。

摘　　要：目的 探讨托吡酯与卡马西平单药治疗癫痫部分性发作的疗效和安全性.方法 计算机检索PubMed、Cochrane、Embase、中国知网、万方数据库和中国生物医学文献数据库中,建库-2019年01月31日关于托吡酯与卡马西平单药治疗癫痫部分性发作患者的临床对照试验文章.对其进行文献筛选,数据提取,文献质量及风险偏倚评估,并交叉核对,使用Meta分析专用软件Revman 5.3进行数据分析.结果 初检文献459篇,最终纳入文献12篇,共2348例患者,其中托吡酯组1075例,卡马西平组1273例.其中高质量文献3篇,低质量文献9篇.Meta分析结果显示:托吡酯组完全控制540例,占52.38%(540/1031);卡马西平组完全控制546例,占45.73%(546/1194),两组差异有统计学意义[OR=1.53,95%CI(1.05,2.24),P<0.05].托吡酯组有效204例,占37.02%(204/551);卡马西平组有效326例,占47.52%(326/686),两组差异无统计学意义[OR=0.91,95%CI(0.70,1.19),P>0.05].托吡酯组出现不良反应372例,占39.45%(372/943);卡马西平组出现不良反应466例,占44.72%(466/1042),两组差异有统计学意义[OR=0.75,95%CI(0.56,1.00),P<0.05].结论 托吡酯单药治疗癫痫部分性发作的疗效及安全性优于卡马西平.Objective To evaluate the efficacy and safety of TPM and carbamazepine in the treatment of partial epilepsy.Methods PubMed,Cochrane,Embase,CNKI,Wanfang database and China Biomedical Literature Database were searched by computer for articles on clinical controlled trials of TPM and CBZ monotherapy for PS before January 31,2019.The literature was screened,data was extracted,literature quality and risk bias were assessed,and cross checked.Data were analyzed using Revman 5.3,a special software for meta-analysis.Results 459 articles were initially checked,and 12 articles were finally includ-ed.A total of 2348 patients,including 1075 in TPM group and 1273 in CBZ group.Among them,3 were of high quality and 9 were of low quality.Meta-a-nalysis showed that 540 cases(52.38%)(540/1031)were completely controlled in TPM group and 546 cases s(45.73%)(546/1194)in CBZ group.There were significant differences between the two groups[OR=1.53,95%CI(1.05,2.24),P<0.05].There were 204 effective cases in TPM group(37.02%)(204/551),326 effective cases in CBZ group(47.52%)(326/686),and there was no significant difference between the two groups[OR=0.91,95%CI(0.70,1.19),P>0.05].There were 372 cases of adverse reactions in TPM group(39.45%)(372/943).466 cases in CBZ group(44.72%)(466/1042),the difference between the two groups was significant[OR=0.75,95%CI(O.56,1.00),P<0.05].Conclusions The efficacy and safety of TPM monotherapy for PS are better than CBZ.

关 键 词：癫痫部分性发作 托吡酯 卡马西平 META分析 

分 类 号：R742.1[医药卫生—神经病学与精神病学] R971.6[医药卫生—临床医学]